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Abstract 
Neurofibromatosis Type 1 is an autosomal disorder of the central and peripheral 
nervous system and affects 1 in 3000 individuals. Patients with the disease have a 
significantly lower quality of life than the general population. Many manifestations of the 
disease contribute to this discrepancy, including anxiety, depression, learning disabilities, 
and cutaneous and plexiform neurofibromas. In addition, due to the number of 
complications that are present, patients need to visit their neuro-oncologists regularly in 
order to ensure that they are in good health. This only adds on to the quality of life 
discrepancy by making patients feel as if the disease is truly taking control of their lives. 
There is no current cure for Neurofibromatosis Type 1, so symptom relief is a priority for 
the time being.  Through a literature review, this thesis assesses the state of current 
psychosocial therapy programs and research related to improving the quality of life of 
patients with Neurofibromatosis Type 1. Incorporation of therapies such as the Relaxation 
Response Therapy, the Acceptance and Commitment Therapy, and the Creative Arts 
therapy have shown to have a significant, positive impact on the quality of life of patients 
with Neurofibromatosis Type 1 and patients with similarly manifesting diseases. These 
findings open the door towards developing new therapeutic programs that contain aspects of 
each of the three previously listed therapies in order to most effectively improve the quality 
of life of Neurofibromatosis Type 1 patients. Although twenty-four relevant sources were 
identified, there is still much research and development that must be done to continue to 
evaluate and improve complementary medicine treatments to better improve the quality of 
life of Neurofibromatosis Type-1 patients.  
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Introduction 
Neurofibromatosis Type 1 (NF1) is a common autosomal dominant genetic disease 
found in humans with a prevalence of 1 in 3,000 individuals (US National Library of 
Medicine, 2018). The disease is caused by mutations in the NF1 tumor suppressor gene and 
is characterized by the presence of multiple neurofibromas (tumors of the nerve sheath, 
which consists of the tissues covering nerves), café au lait spots (skin spots), and freckling. 
Neurofibromas are benign nerve sheath tumors that are expressed intra- or extra-neurally. 
Intra-neural neurofibromas, especially ones that impinge on neighboring organs, 
significantly increase morbidity and mortality by compromising organ functions, whereas 
extra-neural neurofibromas cause cosmetic disfigurement. Other common complications of 
patients with NF1 include malignant transformation of peripheral nerve sheath tumors, brain 
tumors, pain, epilepsy, growth problems, depression, anxiety, and perceptual and 
information processing learning disabilities (US National Library of Medicine, 2018). There 
is currently no cure for the disease, but there are treatment plans to deal with some of the 
complications (US National Library of Medicine, 2018). This highlights a gap in the model 
of care, however, because there currently are no treatment plans that addresses the lower 
quality of life of NF1 patients compared to the general population. 
Quality of life (QoL) is a concept that incorporates all factors that affect an 
individual’s life. Studies have shown that patients with NF1 have a significantly lower 
quality of life compared to individuals without the disease (Ferner et al., 2017). It is 
important to assess the QoL of patients with NF1 in order to improve quality of clinical care 
of these patients. The techniques used to measure the QoL of patients are questionnaire 
based. NF1 and other rare genetic conditions have factors beyond the physical 
manifestations of the disease that contribute to the poor QoL. Psychological well-being, 
coping, and illness perceptions—all of which are exacerbated by the co-morbidity of 
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depression and anxiety—are a few QoL factors that are significantly reduced in NF1 
patients and serve as potential directions of treatment (Ferner et al., 2017).  
Recently, one systematic literature review focusing on patients with rare diseases 
recommends QoL improvement by developing psychosocial interventions to be used in 
conjunction with advancing primary medicine (Cohen et al., 2010). Cohen et al. (2010) 
found that of the factors involved in the concept of QoL, the psychosocial ones are the more 
readily modifiable ones. One potential psychosocial treatment direction is mind-body 
therapy. Mind-body therapy is a therapeutic method designed to enhance the mind’s impact 
on the body in a positive manner (Park et al., 2013). Since depression, anxiety, and other 
manifestations of the disease lead to increased stress and vise-versa, utilization of this 
psychosocial intervention can ultimately improve depression, anxiety, and factors that lower 
NF1 patient’s QoL. Another treatment direction is cognitive-behavioral therapy. Cognitive-
behavioral therapy aims to correct misconceptions attributed towards a certain subject 
(Hollan et al., 1994). Since people respond differently to certain situations based on 
underlying beliefs, the therapy aims to identify and correct areas in an individual’s though 
process that may be overgeneralized, or too pessimistic. Since pain is a common 
manifestation of NF1, utilization of this psychosocial intervention can ultimately improve 
and pain-related QoL deficits a patient may have. 
 The two objectives of this thesis are as follows: First, a review of the literature will 
determine the most significant factors that are associated with the diminished QoL of NF1 
patients. The medium to determine the QoL of a patient is questionnaire-based, and many 
different variations of QoL questionnaires have been developed and used. The difference in 
questionnaires also leads to a difference in factors that are being measured. However, there 
is some overlap between variables, and the data from these questionnaire tools can be 
extrapolated and regrouped to fit a more universal variable. Effectively, the first portion of 
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this literature review aims to unify and standardize the factors associated with the 
diminished QoL of NF1 patients.  
 The second aim of this thesis is to assess publications that aim to improve the quality 
of life of NF1 patients as well as individuals who have similarly manifesting disorders. The 
latter is an important aspect to this thesis because there are treatment methods that certainly 
work for other diseases to improve the quality of life of patients with other diseases, but 
have not yet been considered for the NF1 population. The second part of this literature 
review will essentially attempt to find treatment plans that effectively improve the observed 
QoL discrepancies found in the NF1 population compared to the general population.  
 
Background 
Overview of Neurofibromatosis 
Neurofibromatosis is generally characterized as a disorder that leads to the growth of 
tumors in the nervous system. Neurofibromatosis is divided into three unique diseases: 
Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis.  
Types of Neurofibromatosis 
Neurofibromatosis Type 1 (NF1) is the most common (1 in 3,000 individuals) 
Neurofibromatosis disorder and involves cosmetic and bone structure disfigurement (US 
National Library of Medicine, 2018). The disease is caused by mutations in the NF1 gene. 
NF1 patients develop nerve sheath tumors along the nerves of the skin, brain, and other 
body regions. Optic gliomas (cancer of the optic nerve) are a possible complication. Benign 
growths, called Lisch Nodules appear commonly on the iris as well. Cosmetically, NF1 
patients can have a large variety of cutaneous neurofibromas and café au lait (large freckles 
on the skin) spots on their face and body. The disease usually presents itself during early 
childhood and many development issues such as learning disabilities, ADHD, scoliosis, and 
Using	Psychosocial	Therapy	to	Improve	the	Quality	of	Life	of	Neurofibromatosis	Type	1	Patients	 10	
abnormal bone formation and growth arise as a child with NF1 ages. A patient is formally 
diagnosed with Neurofibromatosis Type 1 if he or she presents with two or more of the 
standard features of the disease (National Institutes of Health (NIH) Consensus 
Development Conference, 1987): 
I. Six or more café au lait spots (dark skin spots) of ≥5 mm in diameter before 
puberty or ≥1.5 mm in diameter after puberty 
II. Axillary or inguinal skinfold freckling 
III. Two or more cutaneous neurofibromas or one plexiform neurofibroma  
IV. Two or more Lisch nodules 
V. An optic pathway glioma 
VI. A first-degree relative (mother, father, or siblings) with Neurofibromatosis Type 1 
Neurofibromatosis Type 2 (NF2) is also characterized by nerve sheath tumors 
along the nerves throughout the body, but the hallmark of the disease is the development of 
vestibular schwannomas or acoustic neuromas along the acoustic nerve, which carries 
information from the inner ear hair cells to the auditory cortex (US National Library of 
Medicine, 2018). The disease is caused by mutations in the NF2 gene. The signs and 
symptoms of NF2 include loss of hearing, tinnitus, and balance issues and do not present 
themselves until adolescence/early adulthood. Although rare, some NF2 patients might also 
develop cataracts during childhood. NF2 occurs in roughly 1 in 33,000 individuals.  
The last form of Neurofibromatosis, called Schwannomatosis, is the development of 
tumors of the Schwann cells of the nervous system (US National Library of Medicine, 
2018). Schwann cells are the specialized cell bodies that insulate nerves to allow successful 
electrical signal transduction. The disease stems from the mutation of two genes, 
SMARCB1 and LZTR1. The signs and symptoms of Schwannomatosis vary depending on 
where the tumor is located. They can include pain, numbness, weakness, tingling, and 
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headaches. The most common symptom is severe chronic pain affecting some region of the 
body. The signs and symptoms do not reveal themselves until early adulthood. The 
incidence of Schwannomatosis has not fully been determined; some populations observe a 
frequency of 1 in 40,000 individuals, while some other populations observe a frequency as 
high as 1 in 1.7 million individuals (US National Library of Medicine, 2018).  
Although certainly each disease constitutes a lowered quality of life for the patient, 
this thesis aims to specifically address the quality of life deficits of patients with 
Neurofibromatosis Type 1. This is because some aspects of each disease are similar, but 
NF1 patients tend to have more complications beyond just tumor development that lead to a 
lowered quality of life such as physical and mental disabilities/disorders. These 
complications will be explained in further detail in the following sections and then related to 
quality of life in the “Concept of Quality of Life in Relation to Neurofibromatosis Type 1” 
section of this thesis. Furthermore, the prevalence of NF1 is significantly higher than the 
prevalence of NF2 or Schwannomatosis. Centering this thesis explicitly on NF1 will 
effectively benefit a large majority of Neurofibromatosis patients.  
Genetic Basis of Neurofibromatosis Type 1 
Neurofibromatosis can best be explained as being a tumor disposition syndrome, 
meaning that individuals with the disease are more likely to develop neurological tumors 
compared to the general population. The genetic basis of the disease stems from the 
mutation of the NF1 gene. These mutations can include missense, nonsense, insertion, and 
deletion mutations (US National Library of Medicine, 2018). Research is still uncovering 
why the NF1 gene mutation causes the variance in the phenotype of neurofibromatosis 
patients, but what is known is that the mutation of the NF1 gene leads to the loss of 
expression of the protein neurofibromin (Kim et al., 2017). The loss of neurofibromin leads 
to the activation of the RAS transcription pathway. RAS signaling and its numerous 
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downstream effectors are known to be involved in the cell cycle and dysregulation of the 
pathway can lead to malignant peripheral nerve sheath tumor formation. Several drugs have 
been developed to closer regulate the RAS pathway in order to suppress the proliferation of 
tumor cells, however no drug has succeeded in showing clinical activity in human patients 
(Kim et al., 2017). Consequently, there is no cure for the Neurofibromatosis Type 1 disease 
at this time (Zale et al., 2018). This emphasizes the importance of developing treatment 
plans that deal with the various complications that NF1 patients deal with for the time being.  
Cancer in Neurofibromatosis Type 1 
Because Neurofibromatosis Type 1 originates from a lack of neurofibromin 
expression, leading to dysfunctional cell cycle monitoring, it is understandable how the 
disease makes patients predisposed to malignant tumor development (Kim et al., 2017). The 
cumulative risk of cancer in all areas for NF1 males and females ages 0-50 is 32.0% and 
45.2%, respectively (Uusitalo et al., 2016). This is significantly higher than those of the 
general population, where cancer risks only reach up to 2.8% for males and 5.0% for 
females (Uusitalo et al., 2016). The cancers that NF1 patients are specifically predisposed to 
are malignant peripheral nerve sheath tumors, gliomas, and leukemia (Korf et al., 2000).  
Malignant peripheral nerve sheath tumors (MPNST) are cancers that develop along 
the nerves from the spinal cord to the body. 81% of MPNSTs arise from preexisting 
neurofibromas and may occur anywhere around the body (Korf et al., 2000). The risk of 
developing a MPNST is significantly increased with NF1. In a clinical study, nearly 52% of 
all MPNSTs were from patients that had NF1 (Ducatman et al., 1986). Typically, surgical 
resection is used to remove the MPNSTs since radiation and chemotherapy do not improve 
the prognosis of cancer patients (Ducatman et al., 1986). Unfortunately, the outcome of 
MPNST is also significantly lower in NF1 patients compared to the general population. The 
5-year survival rate of NF1 patients with MPNST is 16%, which is considerably lower when 
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compared to the 53% in the general population. Additionally, 39% of NF1 MPNST cases 
metastasize to other regions (Ducatman et al., 1986). The difficulty in detecting MPNSTs 
stems from the fact that a majority of them are derived from preexisting neurofibroma 
bodies, and typical MRI scans cannot distinguish between the malignant and non-malignant 
bodies within the neurofibroma.  
NF1 individuals are at high risk for developing optic gliomas (cancer of the optic 
nerve) during infancy and early childhood. Approximately 15-20% of NF1 patients will 
develop an optic glioma during the first 6 years of their life. 6-7% of optic gliomas in NF1 
individuals will progress towards malignancy (Gutmann et al., 2017). Subsequently, if an 
optic glioma forms, it must be carefully monitored every three months to ensure that tumor 
progression does not persist. The deterioration of vision is a possible consequence of a 
growing optic glioma. Careful monitoring of vision is only necessary early on in life, since 
as the individual ages, tumor growth will typically halt altogether. Chemotherapy 
(carboplatin and vincristine) is the primary form of treatment for optic gliomas (Gutmann et 
al., 2017).  
As an NF1 patient reaches adolescence, the risk for brainstem gliomas increases. 5% 
of patients will develop a brainstem glioma (Gutmann et al., 2017). The major complication 
with brainstem gliomas is an obstruction of the ventricles in the brain, leading to 
hydrocephalus (a buildup of cerebrospinal fluid in the brain). Like optic gliomas, brainstem 
gliomas tend to remain static as a patient continues to age.  
Neurological Co-Occurring Disorders 
In addition to the predisposition of neurological tumors, NF1 also holds a 
psychological burden on patients. NF1 patients are more likely to develop numerous 
neurological co-occuring disorders, such as depression, anxiety, attention-
deficit/hyperactivity disorder (ADHD), social perception problems, various types of 
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learning disabilities, and pain compared to the general population. How the disease 
manifests the co-morbidity of these diseases is not well understood. It is speculated, 
however, that the decrease in volume of the white-matter microstructures in the brain might 
in part explain the neurocognitive defects found in NF1 patients (Karlsgodt et al., 2012). 
The white matter in the brain is characterized as neuronal bundles that send information 
from one region of the brain (gray-matter) to other regions (other gray-matter). The loss of 
white-matter volume in the brain might compromise the extent of communication between 
brain regions, ultimately resulting in neurocognitive limitations (Karlsgodt et al., 2012). 
Depression and anxiety in particular seem to commonly present amongst NF1 
patients. One study found 37% of males and 46% of females with the Neurofibromatosis 
disease (NF1, NF2, and Schwannomatosis) to have scored at or above a 16 on the Center for 
Epidemiologic Studies Depression (CESD) Scale, which suggest clinical depression (Wang 
et al. 2012). A larger study, done by Cohen et al. 2015, found that 55% of all NF1 patients 
(61% of women and 43% of men) scored at or above the threshold score of 16 on the CESD 
scale. Additionally, Johnson et al., (1999) found that 16% of children of NF1 have suicidal 
thoughts, which is significantly higher than the 3% observed in the general population. 
Attention-deficit/hyperactivity disorder (ADHD) is a neurocognitive disorder that 
results in inattentive behavior, hyperactivity, and impulsivity. ADHD is prevalent in about 
30-50% of children with NF1. The disorder manifests itself strongly in the classroom 
setting—NF1 Children with ADHD have much more difficulty following complex 
instructions by their teacher, and have trouble learning how to read and do mathematical 
calculations (Cohen et al., 2015). The complications associated with ADHD persist past 
childhood and adolescence and carry over into adulthood. Furthermore, one study found that 
NF1 patients with ADHD had lower life satisfaction, more excitability, aggressiveness, and 
more emotional instability than NF1 patients that did not have ADHD. The study also found 
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that NF1 patients with ADHD appeared to be more emotionally unstable compared to 
ADHD patients without NF1. (Mautner et al., 2015). Emotional stability is an important 
factor to consider for coping with chronic diseases. Since NF1 is a chronic, neurological 
disorder, NF1 patients with ADHD are at a high risk for psychological morbidity.  
In addition to ADHD, NF1 patients have additional learning disabilities that are 
more prevalent than in the general population. 81% of children with NF1 have cognitive 
impairment in at least one area of cognitive functioning. 51% of children with the disease 
had a poor performance in reading, spelling, and mathematic tasks, and 20% of the children 
were diagnosed with a specific learning disability, a two and a half times higher rate than 
found in the general population (Hyman et al., 2005). A specific learning disability is a 
deficit in one of the following eight domains: oral expression, listening comprehension, 
basic reading, reading comprehension, reading fluency, written expression, mathematical 
calculation, and mathematical problem solving (Colorado Department of Education, 2018). 
Lastly, it was found that both fine motor skills and motor speed was reduced in NF1 
children. Hyman et al., (2006), constructed a neuropsychological profile for NF1 children 
that consist of visuospatial and visuoperceptual deficits, executive functioning deficits, and 
attention deficits. Treatment of the learning disabilities found in NF1 patients is crucial to 
begin at an early age in order to ensure that the children do not have continual learning 
discrepancies later on during adolescence and adulthood (Hyman et al., 2006). The 
underlying cause of these deficiencies (including ADHD) have not yet been explained, but it 
is hypothesized that it is related to lower dopamine levels as a result of a lack of 
neurofibromin expression. The biallelic loss of the NF1 gene in mice models has shown to 
cause defects in hippocampal learning and brain attention system functioning (Diggs-
Andrews et al., 2013). Furthermore, in studies using knock-out mice models, dopamine 
uptake inhibitors have shown to ameliorate the hippocampal learning and attention system 
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defects. But these drugs have shown to be ineffective in improving learning during clinical 
trials (Gutmann et al., 2017), highlighting a gap in NF1 treatment.   
NF1 patients also exhibit social deficits. This leads to poor social participation, peer 
relationships, and self-esteem. Roughly 40% of NF1 children show autism spectrum 
disorder-like symptoms and 13% are diagnosed with autism (Garg et al., 2013). These high 
statistics may partially explain NF1 patient’s social behavior, as one symptom of autism is 
the difficulty to decipher the emotional state of others. Additionally, NF1 children are 
reported by their parents and teachers to have more limited social skills compared to their 
peers (Johnson et al., 1999). These social deficits continue to present themselves into 
adulthood. Namely, it is the lack of prosocial behavior (using eye contact, showing interest 
in what others are saying, etc.) that leads to the social problems faced by NF1 patients and 
not an increase in antisocial behavior (rudeness, insensitiveness, arguing, etc.). These 
deficits were found to be more prevalent in males compared to females (Pride et al., 2013). 
The social behavior exhibited by NF1 patients is believed to be due in part to the 
impairments in executive and attention functioning.  
A great deal of pain also arises from plexiform neurofibromas as they can press 
against vital organs and sensitize the noicireceptor activity of those organs. Surgical 
intervention may be an option to correct the cosmetic disfigurement or alleviate pain, but is 
not always feasible. Surgical resection of neurofibromas might be impossible to execute if 
the neurofibromas are too large, too many, too inaccessible, or too close to vital body 
structures. There are two drugs, Sirolimus and Selumetinib, currently undergoing clinical 
trials that aim to alleviate the pain induced by plexiform neurofibromas. Sirolimus has 
shown effectiveness in reducing pain levels but did not succeed in decreasing the size of the 
plexiform neurofibromas (Hua et al., 2014). The drug was, however, only administered in 
cases of extreme pain and was used only if surgical intervention was not an option. In 
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patients who were administered Selumetinib, there was an observed decrease in tumor size, 
pain, disfigurement, and functional impairment of subjects after treatment (Dombi et al., 
2016). But again, these drugs are only under clinical trials at the moment and are not 
accessible for every NF1 patient. Indeed, a number of neurofibromatosis patients are 
prescribed painkillers to deal with their pain, which can potentially pose larger health risks 
associated with opioids and opioid addiction (Paice et al., 2018).  
Cosmetic Disfigurement 
Although some tumors that NF1 individuals have may be benign, this does not mean 
that they do not lower their quality of life. Many benign neurofibromas can reveal 
themselves cutaneously, leading to displeasing cosmetic disfigurements (Wolkenstein et al., 
2001). Cutaneous neurofibromas may be presented in certain regions or all over the body 
and the frequency of cutaneous neurofibromas presenting themselves are highly variable 
from patient-to-patient. The cause of high variability in the number of neurofibromas is still 
unknown. The social stigma caused by the cutaneous neurofibromas can lead to patients 
being labeled as “freaks” or social outcasts. This may have an effect on a NF1 patient’s 
social and emotional functioning and can be a potential reason why many neurofibromatosis 
patients have depression.  
Some neurofibromatosis patients may also experience precocious puberty during 
childhood, followed by stagnated growth during adolescence and shortened height during 
adulthood. Although not necessarily a cosmetic disfigurement, the stunted height associated 
with the disease may contribute to the body-image issues seen by many NF1 patients 
(Cohen et al., 2015). This pattern of linear accelerated growth may occur in patients who 
develop optic chiasm pathway gliomas due to an increase in growth hormone production. 
Adult height can be preserved, however, with careful monitoring of pediatric growth charts 
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and administration of a luteinizing hormone-releasing hormone (a growth promoting 
hormone) agonist (Gutmann et al., 2017). 
Of the many bone deformities that NF1 patients are at risk for, such as osteopenia 
(lower bone density) or osteoporosis (weakening of bones), tibial dysplasia (bowing of the 
leg bone) is the most significant. The bowing of the tibia can cause a noticeable cosmetic 
deformity and a weakened bone that is prone to fractures (Gutmann et al., 2017). 
Consequently, patients with tibial dysplasia will typically need to have an Ilizarov external 
fixation brace in order to realign the bone and allow for proper healing. The brace itself is 
strikingly more noticeable than the bowing of their legs and can be a continual reminder to 
the patient of their condition. Additionally, this places patients in a situation where playing 
physical sports is very dangerous for them. The condition stems from defective bone 
mineral production. Currently, a drug named BMP2 has proven to correct these defects in 
bone remodeling in NF1 knock-out mice strains, however clinical trials are still to be 
approved.  
 
The Concept of Quality of Life in Relation to Neurofibromatosis Type 1 
  According to the World Health Organization (WHO), quality of life is defined as:  
“An individual's perception of their position in life in the context of 
culture and value systems in which they live in relation to their goals, 
expectations, standards, and concerns affected in a complex way by 
the person's physical health, psychological state, level of 
independence, social relationships and their relationships to salient 
features to their environment.”  
 QoL can essentially be interpreted as how “happy” a patient is with their life. It is 
difficult to make an objective assessment of an individual’s QoL, which is instead 
Using	Psychosocial	Therapy	to	Improve	the	Quality	of	Life	of	Neurofibromatosis	Type	1	Patients	 19	
determined by physicians through questionnaires that incorporate physical, psychological, 
and social variables. Some of the questionnaires include The Pediatric Quality of Life 
Inventory (PedsQL), Short Form 36 health survey (SF-36), TNO AZL Children's Quality Of 
Life (TACQOL), and the Impact of NF1 on Quality of Life (INF1-QOL). 
 When considering all of the complications, both mental and physical, that NF1 
patients have to deal with, it is understandable that they might have a lower QoL compared 
to the general population (Page et al., 2006). Cancer, in particular the malignant peripheral 
nerve sheath tumors, certainly negatively effect an individual’s outlook on life due to the 
psychological burden associated with the possibility of not surviving. The risk of severe 
visual deficits and blindness by optic gliomas can also be understood as a potential area that 
can lower a patient’s QoL. The neurological co-occuring disorders may have a significant 
effect on a NF1 patient’s QoL as well. Depression and anxiety certainly may alter an 
individual’s outlook on life, making it hard to find life enjoyable because of his or her 
mood. ADHD and other learning disabilities may also affect one’s perception of life. 
Learning disabilities can take an emotional toll on an individual, making them feel as if they 
are not smart enough or inadequate in a particular subject. When comparing themselves to 
their normal peers who do not have as much trouble learning, it makes sense that this aspect 
of the disease could lower the individual’s QoL. Lastly, the cosmetic disfigurement caused 
by the cutaneous neurofibromas, stunted growth, and bowed legs may be potential catalysts 
for bullying and social exclusion. These hinder many physical, psychological, and social 
aspects of a NF1 patient’s life and may account for a diminished QoL. To add on to all of 
the psychological stress that this disease creates, patients are also reminded that there is no 
cure for the disease, meaning that whatever complications they have are more than likely 
here to stay. Thus, while there is still no cure for NF1, the one aspect of patient’s lives that 
can be adjusted is their quality of life. It is critical for the healthcare sector to establish 
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treatment options for the NF1 population in order to raise their QoL while researchers 
continue to learn more about this rare disease.  
Methods 
Sources 
 An initial search was performed using the Medline (EBSCO) database, a database 
consisting of peer-reviewed biomedical literature, using the following terms: 
Neurofibromatosis, quality of life, well being, skin diseases, oncology, complementary 
medicine, psychosocial therapy, cognitive-behavioral therapy and mind-body therapy. The 
first two terms were primarily used to identify any literature that assesses the quality of life 
of NF1 patients while the rest of the terms were directed towards identifying treatment 
methods that help improve the QoL of patients. Another search was conducted using the 
Google Scholar database using the same terms. Google Scholar has a feature that 
automatically includes synonyms of each given terms in the search so additional sources 
were identified beyond the scope of the specific terms listed above. Lastly, additional 
relevant sources were found by reviewing the reference lists of found publications. The first 
thirty relevant matches were reviewed in each search due to the trend of a loss of topic 
relevance after the first thirty matches on average.  
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Selection and Assessment Criteria 
 Publications were included in the literature review if they met the criteria listed 
below: 
I. The study population focused on, or at least included, patients with NF1 for 
QoL assessment. 
II.  A standardized QoL measure is used to assess the QoL of the studied 
population. 
III. The study focused on the utilization of a complementary medicine treatment 
method in an attempt to improve the QoL of patients.  
IV. The treatment method employed on the disorder population being studied has 
similarly manifesting characteristics as NF1.  
V. The treatment method employed on the disordered population attempts to 
measure a quality of life change throughout the course of treatment.  
VI. The study was a peer-reviewed publication. 
VII.  The study is available in English. 
VIII.  The study was published after January 1st, 2000. 
 The topic criterion was included in the database search and was screened for 
manually as well. Criteria V did not require a standardized QoL measure due to the lack 
of publications addressing changes in QoL domains through QoL-assesssing 
questionnaires. Instead, more specific questionnaire measures, such as the Center for 
Epidemiological Studies Depression Scale (CES-D scale), which measures the level of 
depression an individual has, were used instead to measure improvements in QoL 
domains.  
 
 
Using	Psychosocial	Therapy	to	Improve	the	Quality	of	Life	of	Neurofibromatosis	Type	1	Patients	 22	
Results 
Selections 
 The search of the Medline (EBSCO) and Google Scholar databases to assess the 
diminished QoL of NF1 patients yielded seventy-six results. Of these seventy-six results, 
sixty-three did not meet the inclusion criteria. Seventeen of these did not address individuals 
with Neurofibromatosis type-1, thirty-two did not address quality of life, eleven were case 
studies, and three were not in English. This left thirteen remaining abstracts that met the 
inclusion criteria for the assessment of QoL in NF1 patients. The full-texts were then 
assessed for further eligibility. Four studies did not have a standardized measure to assess 
quality of life and were thus excluded from the review, leaving nine studies remaining in the 
review.  
 The search of the Medline (EBSCO) and Google Scholar databases to assess 
publications that aim to improve the quality of life of NF1 patients as well as individuals 
that have similarly manifesting disorders yielded ninety-seven results. Eighty-one did not 
meet the inclusion criteria. Of these, fifty-four pertained to diseases that were not similar to 
NF1, twelve did not employ complementary medicine techniques, ten did not focus on 
measuring improvement in QoL during the treatment program, three were case study 
reports, and two were not in English. This left sixteen remaining abstracts that met the 
inclusion criteria for the assessment of treatment methods that can improve the QoL of NF1 
patients and patients with similarly manifesting characteristics. The full-texts were assessed 
to ensure there was a sufficient qualitative method to measure QoL improvement, such as 
the CES-D scale to assess changes in depression or the Pain Interference Index to assess 
changes in pain thresholds. One study did not have a qualitative method to measure QoL 
improvement and was thus removed from the literature review, resulting in fifteen relevant 
publications. Figure 1 illustrates the literature review processes.  
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Figure 1 
Literature Review Selection Process for: a.) QoL assessment of NF1 patients and b.) 
Treatment methods to improve QoL 
 a.)        b.) 
 
 
 
 
 
 
 
 
 
 
 
Quality of Life Assessment in Patients with Neurofibromatosis Type 1 
In total, nine relevant sources were identified in this section of the literature review. 
Four peer-reviewed publications studied children and adolescents with NF1 (n = 4), while 
six publications addressed adults  with NF1 (n = 5). In eight of the studies (n = 8), the NF1 
patient population was being compared to the QoL scores of the general populations, all of 
which displayed a diminished quality of life in nearly every domain of the questionnaire. 
Ferner et al. (2017) aimed to produce an NF1-specific QoL questionnaire, which was 
compared to a previously developed QoL questionnaire to test internal reliability. Cohen et 
al. (2015) measured the internal variance between specific domains of the QoL index and 
how it contributes to the overall variance in QoL scores for NF1 patients. The validated 
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instruments used to measure QoL in these publications were either general measures or 
disease-specific measures. Some general measures used the Short-Form 36 Questionnaire 
(SF-36), the PedsQL, TNO-AZL Questionnaire for Children Health-Related QoL, and the 
Child Health Questionnaire. The Skindex and the Impact of NF1 on Quality Of Life 
Questionnaire (INF1-QOL) are NF1-specific questionnaire tools. The former is used 
primarily in NF1 patients who have facial or external deformities as a primary marker of 
their disease. The general measures are used as good indicators on the general functioning 
of a patient while the more specific questionnaire measures help pinpoint more of the 
disease-specific symptoms in relation to overall QoL. In total, one thousand three hundred 
and twenty-one (n = 1,321) patients with NF1 were surveyed. The takeaway from this part 
of the literature review was that patients with NF1 had significantly lower QoL scores in 
nearly every domain of the QoL Questionnaire that was used. Table 1 displays the literature 
review results.  
Table 1 
QoL Literature Review Results 
Study & Location Participants Questionnaire  
Type 
General Conclusion 
Cipolletta et al., 
2017 
Northern Italy 
Children and 
Adolescents 
(n = 60) 
PedsQL Subjects have a significantly lower QoL 
score in all areas of the PedsQL 
Questionnaire. The most profound 
differences were in social life, physical 
health, and school activities. 
 
Cohen et al.,  
2015 
United States 
Adults 
(n = 498) 
QoL Index Depression accounts for approximately 32%  
of the total variance in QoL scores for NF1 
patients.  
 
Ferner et al., 
2017 
United States 
Adults 
(n = 50) 
INF1-QOL Highest impacts on QoL of NF1 patients are 
depression and anxiety (32%) and the  
negative effects of NF1 on 
the role and outlook on life (42%). 
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Graf et al.,  
2006 
Netherlands 
Children and 
Adolescents 
(n = 46) 
TNO-AZL  
QoL 
Subjects have a significantly lowered QoL 
score in most domains of the questionnaire. 
Namely, motor, cognitive, emotional, and 
social functioning. Subjects also had higher 
scores in internalizing and externalizing  
factors. 
 
Krab et al., 
2008 
Netherlands 
Children and 
Adolescents 
(n = 58) 
Child Health 
Questionnaire 
(CHQ) 
NF1 children experienced the largest  
deviances from normal population QoL in 
general health perception, physical 
functioning, role functioning, mental health,  
and self-esteem. 
 
Merker et al., 
2014 
United States and 
Germany 
Adults 
(n = 142, 107 
from the USA, 
and 35 from 
Germany) 
SF-36 Internal tumor volume does not contribute  
to a diminished QoL but instead is caused  
by psychosocial factors. The most  
profound differences in QoL scores  
in comparison to the general US population 
were physical role, emotional role,  
mental health, and physical functioning. 
 
Oostenbrink et 
al., 2007 
Netherlands 
Young  
Children 
(n = 34) 
ITQoL  NF1 children experienced the most  
significant deviations from the general  
Dutch population in the general health 
perceptions (large effect), growth and 
development (moderate effect), and physical 
functioning (moderate effect) domains. 
 
Page et al., 
2006 
United States 
Adults 
(n = 176) 
SF-36 and 
Skindex 
SF-36: Patients had a significantly lower  
QoL score for all domains of the 
questionnaire. The most profound differences 
were in physical functioning, emotional role, 
general health, and mental health domains. 
Skindex: As NF1 visibility increases, so does 
the skin diseases’ effects on each aspect of  
their QoL(emotion, symptoms, and 
functioning). 
  
Wolkenstein et 
al.,2001 
France 
Adults 
(n = 128) 
 
SF-36 and 
Skindex 
SF-36: Patients had a significantly lower  
QoL score for all domains of the  
questionnaire. The most profound differences 
were in mental health, emotional role, social 
functioning, and general health perceptions. 
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Skindex: Participants with more visible NF1 
reported more effects of skin disease on each 
aspect of their QoL (emotion, symptoms,  
and functioning). 
Quality of Life Findings 
 Overall, the literature review of the ten publications addressing the QoL of NF1 patients 
finds patients with NF1 to have a significantly lower QoL compared to the general 
population in nearly every domain of each questionnaire tool. The majority of studies used 
the SF-36 to assess the QoL discrepancies between the general population and patients with 
NF1. Because of how general each domain of the SF-36 questionnaire is, the questionnaire 
will serve as a sufficient template in determining the most significant determinants of a 
diminished quality of life. The results from other survey tools will be categorized into one of 
the eight specific domains of the SF-36 questionnaire to determine the most significant 
aspects of QoL that are diminished in the NF1 population. Thus, before continuing, each 
domain of the SF-36 questionnaire must be addressed.  
 The SF-36 questionnaire is divided into eight scaled scores (vitality, physical 
functioning, bodily pain, general health perceptions, physical role functioning, emotional 
role functioning, social role functioning, and mental health). Vitality measures the level of 
energy/fatigue a patient experiences. Physical functioning measures the extent at which 
patients are able to perform physical activities such as walking, running, lifting heavy 
objects, and bathing/dressing themselves. Bodily pain indicates to what extent the patient’s 
experience of pain hinders their performance of everyday activities. General health 
perception measures how healthy the patient believes they are relative to other people they 
know. Physical role functioning refers to the extent to which performance of roles in the 
patient’s daily life is affected by their physical state of health. Emotional role functioning 
assesses the extent to which the emotional condition of the patient limits their daily 
functioning. Social role functioning refers to the social interactions with family members, 
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friends, neighbors, and other social relations. Lastly, Mental Health measures the extent to 
which an individual is feeling both positive and negative emotions. Due to the similarities 
between physical functioning and physical role functioning (the primary difference being 
the patient’s perception vs. the patient’s performance on the success of every day physical 
activities due to their condition), these two will be grouped together when categorizing data 
from other questionnaire tools that are not a part of the SF-36 questionnaire. Furthermore, 
due to the similarities between the emotional role functioning and mental health domains 
(the extent to which emotions effect daily life and the extent at which one is feeling happy 
or sad), these two will be grouped together as well. 
 Three studies (Merker et al., 2014, Page et al., 2006, and Wolkenstein et al., 2001) used 
the SF-36 questionnaire to measure the QoL of NF1 patients. The findings amongst these 
three publications reveal that the most significant domains of the SF-36 questionnaire that 
impact the QoL of NF1 patients are general health perceptions, mental health, social 
functioning, emotional functioning (grouped with mental health), and physical functioning. 
In addition, Page et al. (2006) and Wolkenstein et al. (2001), also found through the Skindex 
questionnaire that these domains are more significantly impacted when the visibility of 
neurofibromas are more prevalent.  
Amongst the studies for children with NF1, Cipolletta et al. (2017) found that children 
with NF1 scored significantly lower in all areas of the PedsQL Questionnaire, with the most 
profound differences being in social life (social functioning), physical health (physical 
functioning), and school activities. Graf et al. (2006) utilized the TNO-AZL QoL 
questionnaire and found that NF1 patients scored significantly lower in all domains of the 
questionnaire with the most profound differences being in the motor functioning (physical 
functioning), cognitive functioning, emotional functioning (mental health), and social 
functioning domains of the questionnaire. Additionally, patients also had higher scores in 
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internalizing and externalizing behaviors. Higher rates of internalizing behavioral problems 
equate to a patient experiencing more social withdrawal (social functioning) and more 
depressive and anxiety symptoms (mental health). Higher rates of externalizing behavior 
equates to more aggression and dissocial behavior (social functioning). Through utilization 
of the Child Health Quesitonnaire, Krab et al. (2008) found that the largest deviances NF1 
patients experienced from the normal population in QoL were general health perception, 
physical functioning, mental health, and self-esteem (can be grouped with mental health). 
Lastly, Oostenbrink et al. (2007), found through the Infant/Toddler Quality of Life 
Questionnaire, that NF1 children experience the most significant deviations from the general 
Dutch population in general health perceptions, growth and development (can be grouped 
with physical functioning), and physical functioning.  
Among the remaining publications with adult subjects, Cohen et al. (2015) found that 
depression accounts for approximately 32% of the total variance in the QoL scores for NF1 
patients using the QoL Index questionnaire (mental health). Furthermore, Ferner et al. 
(2017) confirm that the highest impacts on QoL in NF1 patients are depression and anxiety 
(mental health) as well as the negative effects of NF1 on the role and outlook on life 
(general health perceptions) of these patients. 
The QoL literature review findings reveal that the most significant factors that contribute 
to the diminished quality of life in NF1 patients are physical functioning, mental health, 
social functioning, and general health perceptions. Table 2 reveals the frequency of each 
category that is deemed to cause a profound difference between the general population and 
the NF1 population. Note is that in nearly every publication, there was a significant 
difference in all domains of QoL (including vitality and bodily pain in the SF-36 
questionnaire studies), but table 2 is primarily concerned with the most significant 
discrepancies in each domain. Having determined the most significant factors associated 
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with the diminished quality of life of NF1 patients, potential treatment methods can be 
reviewed and analyzed in order to determine their effectiveness in improving these domains 
of quality of life.  
Table 2 
Number of Publications in which there is a significant discrepancy between general and 
NF1 population in each generalized domain of QoL. 
Vitality Physical 
Functioning 
Mental  
Health 
Social 
Functioning 
Bodily Pain General Health 
Perceptions 
0 8 8 7 0 7 
 
Treatment Plan Assessment in Improving the Quality of Life of Patients with 
Neurofibromatosis Type 1 
 In total, fifteen publications were reviewed that address treatment plans that improve 
domains of QoL (N = 15). Amongst the fifteen publications, there are two general types of 
therapies: Mind-Body therapies (n = 9), and Cognitive Behavior therapies (n = 6). The 
diseases of patients undergoing these therapies include Neurofibromatosis Type 1 (n = 4), 
Neurofibromatosis Type 2 and Schwannomatosis (n = 1), Cancer (n = 3), Irritable Bowel 
Syndrome (n = 1), Fibromyalgia (n = 2), Bipolar Disorder (n = 1), Depression (n = 1), and 
general chronic illness and mental health issues (n = 2). The questionnaire measures varied 
from study-to-study due to the variations in the disease studied as well as treatment goals, 
but each can be related to a QoL domain from the SF-36. These questionnaires were 
performed pre-test and post-test to measure any changes. In total, two thousand seven 
hundred and eighteen patients (n = 2,718) underwent a treatment program for their 
complication. Table 3 displays the literature review results.  
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Table 3 
Treatment Plans Literature Review Results 
Study & Location Participants  
& Disease 
Treatment  
Type 
Questionnaires  
Used 
General Conclusion 
Decker et al., 
1992 
United States 
 
Adults with 
Cancer 
(n = 82) 
Relaxation  
Therapy 
(Mind-Body 
Therapy) 
Profile of Mood  
States 
There is a significant 
reduction in tension, 
depression, anger, and  
fatigue in cancer patients 
undergoing radiation  
therapy. 
 
Kuo & Bhasin et 
al., 2015 
United States 
Adults with 
Irritable  
Bowel  
Syndrome  
(IBS) 
(n = 48) 
Mind-Body  
Therapy 
Trait Anxiety 
Scores, IBS QoL, 
IBS Symptom 
Severety Index,  
IBD  
Questionnaire 
Anxiety, quality of life,  
and symptom severity  
scores improved 
significantly post 
intervention and at  
short-term follow-up 
appointments. 
 
Luciano et al.,  
2013 
Spain 
 
Patients with 
Fibromyalgia 
(n = 156) 
Group 
Acceptance & 
Commitment 
Therapy 
(Cognitive 
Behavior 
Therapy) 
Fibromyalgia 
Impact 
questionnaire,  
Pain  
Catastrophizing 
Scale, Hospital 
Anxiety and 
Depression Scale, 
Pain visual  
analogue scale,  
EuroQoL 
 
Subjects showed in 
improvement on  
coping with the  
disease, and reduced  
pain levels.  
Madden et al., 
2010 
United States 
Children with 
Brain Tumors 
(n = 16) 
Creative  
Arts  
Therapy 
(Mind-Body  
Therapy) 
Faces Scale and 
Emotional 
Responses  
Checklist  
Subjects showed an 
improvement in pain 
tolerance and were  
more excited, happier,  
and less nervous. 
 
Martin et al.,  
2016 
United States 
Children with 
NF1  
(n = 17) 
Acceptance  
And 
Commitment 
Therapy  
(Cognitive 
Behavior 
Modified Brief  
Pain Inventory,  
Pain Interference 
Index, Acceptance 
of Pediatric  
Disease 
Patients reported  
significant declines in  
pain interference at 3 
months post-treatment. 
Pain intensity declined 
from baseline and  
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Therapy) Questionnaire 
 
parents reported greater 
acceptance of their  
child’s pain. 
Miller et al.,  
2015 
United States 
Adults with 
Depression 
(n = 24) 
Mind-Body 
Therapy 
Center for 
Epidemiological 
Studies  
Depression Scale, 
Health-Promoting 
Lifestyle Profile  
II, QoL-5 
Significant post- 
treatment improvements 
were shown for  
depression, spiritual 
growth, mental health,  
and quality of life. 
 
 
Noroozi et al.,  
2017 
Iran 
 
Patients with 
Type 2  
Diabetes 
comorbid with 
Depression 
(n = 30) 
 
Group 
Cognitive 
Behavior 
Therapy 
Beck Depression 
Inventory, World 
Health  
Organization QoL 
Intervention group 
experienced a decline  
in depressive  
symptoms as well as  
an improved quality of  
life compared to the 
control group. 
 
Pankowski et al., 
2017 
United States 
Patients with 
Bipolar  
Disorder 
(n = 26) 
 
Group 
Acceptance & 
Commitment 
Therapy 
(Cognitive 
Behavior 
Therapy) 
 
The Beck Anxiety 
Inventory, The  
Beck Depression 
Inventory, QoL 
Inventory, 
Acceptance and 
Action 
Questionnaire 
 
Patients reported 
significant  
Improvements in  
anxiety, depression,  
quality of life, and 
psychological  
flexibility. 
Puetz et al., 2013 
United States 
 
Patients with 
Cancer  
(n = 1576) 
Creative Arts 
Therapy 
(Mind-Body 
Therapy) 
Trait anxiety  
scores, Center for 
Epidemiological 
Studies  
Depression Scale, 
Pain intereference 
index 
 
Treatment significantly 
reduced anxiety, 
depression, pain, and 
increased quality of  
life.  
Samuelson &  
Foret et al., 2010 
United States 
 
Mental health 
outpatients 
(n = 331) 
Mind-Body 
Therapy 
Medical Symptom 
Checklist, Health 
Promoting  
Lifestyle Profile 
Significant post- 
treatment improvements in 
symptom frequency,  
health responsibility, 
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II, and Symptom  
Checklist- 90R  
spiritual growth,  
nutrition physical  
activity, relationships, 
stress management, 
depression and  
anxiety. 
 
Vranceanu et 
al., 2014 
United States 
 
Adults with  
NF1, NF2, and 
Schwannoma-
tosis 
(n = 20) 
Relaxation 
Response 
Resiliency 
Program 
(Mind-Body 
Therapy) 
Satisfaction with  
life scale, 
Resiliency scale, 
Perceived stress 
scale, Epworth 
sleepiness scale,  
and Patient- 
Health 
Questionnaires  
for Depression,  
Somatic  
Symptoms, and 
Anxiety 
 
Significant post- 
treatment improvement  
in resiliency, satisfaction 
with life, stress, 
depression, anxiety, 
somatization, sleepiness, 
mindfulness, and post 
traumatic growth  
(effect sizes ranging  
from moderate to  
high). 
 
 
Vranceanu et 
al., 2014 
United States 
Adults with 
chronic  
physical,  
mental and co-
morbid health 
issues.  
(n = 226) 
Mind-Body 
Therapy 
Medical 
Symptoms 
Checklist, Health 
Promoting 
Lifestyle Profile, 
Symptom 
Checklist 90R 
 
Patients showed  
significant improvement 
on 9/23 medical 
symptoms, all health 
promoting lifestyle 
behaviors, and all mental 
health symptoms. 
Vranceanu et 
al., 2016 
United States 
 
Adults with  
NF1 
(n = 63) 
Relaxation 
Response 
Resiliency 
Program for 
patients with 
NF1 via 
Videoconfer-
encing 
(Mind-Body 
Therapy) 
World Health 
Organization QoL 
abbreviated 
instrument, 9-item 
Patient Health  
Questionnaire for 
Depression, 
Generalized  
Anxiety Scale,		
Brief Pain  
Inventory 
Patients participating  
in the 3RP-NF  
program showed  
greater improvements 
compared to the 
control mind-body  
therapy program in 
psychological, 
environmental, and  
social QoL as well as 
anxiety. Both treatment 
programs showed 
improvement in  
depression and pain 
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intensity. These 
improvements  
sustained themselves 
during the 3-month  
follow-up period. 
 
Wicksell et al.,  
2012 
Sweden 
 
Adults with 
Fibromyalgia 
(n = 40) 
Acceptance & 
Commitment 
Therapy 
(Cognitive  
Behavior 
Therapy) 
 
Fibromyalgia 
Impact 
questionnaire,  
Pain  
Catastrophizing 
Scale, Hospital 
Anxiety and 
Depression Scale, 
Pain visual  
analogue scale,  
EuroQoL 
 
Patients in the ACT  
group showed  
significant differences 
in pain‐related  
functioning, mental  
health‐related QoL, 
depression, and  
anxiety. 
Zale et al., 
2017 
United States 
Adults with  
NF1 
(n = 63) 
Relaxation 
Response 
Resiliency 
Program for 
patients with 
NF1 
(Mind-Body 
Therapy) 
Measure of 
Current Status-
A, The Medical 
Outcomes Study 
Social Support 
Survey, The 
Gratitude 
Questionnaire, 
Life Orientation 
Test Optimism 
Scale  
 
 
Patients who received 
the 3RP-NF program 
vs. the control mind- 
body therapy program 
reported more  
substantial  
improvements in  
perceived coping  
abilities, perceived  
social support, and 
mindfulness. These 
improvements sustained 
themselves during the 6-
monthfollow-up period.  
 
 
Mind-Body Therapies 
 Nine publications utilized a mind-body therapeutic approach towards improving the 
QoL or symptoms of the patients’ disease. Mind-body therapies focus on the cooperation 
between the mind and the body in the experience of a stress response in order to effectively 
suppress the stressor. Two specific types of mind-body therapies were identified: The 
Relaxation Response and Resiliency Program and the Creative Arts Therapy. 
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 The Relaxation Response is characterized by a decrease in the arousal of the 
sympathetic nervous system (Park et al., 2013). Stress involuntarily activates the 
sympathetic nervous system, which leads to an increase in cortisol, norepinephrine, and 
epinephrine levels, ultimately leading to an increase in metabolism, blood pressure, and 
heart rate. The relaxation response, on the other hand, combats these responses, and has the 
opposite effect. The importance of the relaxation response boils down to how human stress 
effects the allostatic load of the brain. Allostasis refers to the capacity of the brain to 
maintain a stable physiological state in the face of environmental changes, such as stress. 
When an individual is experiencing a stressful situation, the brain expends a great deal of 
energy to combat the stressful situation and allow the brain to return back to the baseline 
state. The consequence is metabolic wear and tear, however, making the brain less effective 
in combatting a second stressful response until a sufficient amount of time passes to allow 
the brain to return to the baseline state. This is where chronic stress or severe exposure to a 
higher metabolic state comes into play; with continual stressors cueing the brain to maintain 
homeostasis, there is an inability to return back to baseline due to a lack of time for the brain 
to recover from the stressful cue. This eventually leads to an increase in allostatic load, 
which has been shown to increase the vulnerability to illness (Park et al., 2013). Eliciting the 
relaxation response however has been shown to reduce the allostatic load of a stressful 
situation by buffering the heightened metabolic state of the stress response (decrease in 
sympathetic arousal). The relaxation response can be elicited in numerous ways, including 
meditation, yoga, and muscle relaxation (Park et al., 2013) and is the basis of the mind-body 
therapy techniques employed by the publications identified in this literature review.  
 The Relaxation Response and Resiliency Program is a mind-body approach that 
elicits the relaxation response. There are five non-NF1 publications that utilize the 
Relaxation Response in order to improve the QoL of their patients. Decker et al. (1992) 
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showed that relaxation therapy resulted in a significant reduction in depression, anger, and 
fatigue in cancer patients undergoing radiation therapy. In the scope of the SF-36 domains 
for QoL, this equates to an improvement in mental health (depression and anger), as well as 
vitality (fatigue). Kuo & Bhasin et al. (2015) showed that relaxation therapy in adults with 
Irritable Bowel Syndrome experienced a decrease in anxiety (mental health), and symptom 
severity (bodily pain) as well as an increase in QoL of these patients. Miller et al. (2015) 
used relaxation therapy on patients with depression and found significant post-treatment 
improvements for QoL, mental health, and depression. Vranceanu et al. (2014) showed that 
mind-body therapies improve the health-promoting lifestyle behaviors (general health 
perceptions) and mental health symptoms (mental health) of adults with chronic physical, 
mental, and comorbid health issues. Lastly, Samuelson & Foret et al. (2010) showed 
improvements in symptom frequency (mental health), health responsibility, physical activity 
(physical functioning), nutrition, interpersonal relations (social functioning), stress 
management (mental health), and depression and anxiety (mental health) in mental health 
outpatients.  
 In addition to the five Relaxation Response Therapies listed above, there were three 
publications that specifically addressed the NF1 population. Vranceanu et al. (2014) showed 
an improvement with resiliency, satisfaction with life, depression and anxiety, and stress 
(mental health) after the intervention for patients with NF1. Additionally, Vranceanu et al. 
(2016) implemented the Relaxation Response Therapy for NF patients via 
videoconferencing, and not only observed a higher turnout rate of participants compared to 
the non-videoconferencing group in Vranceanu et al. (2014) but also an improvement in 
psychological, environmental, and social QoL as well as anxiety (social functioning and 
mental health). Lastly, Zale et al. (2017) found that patients who received the 3RP-NF 
program compared to the control mind-body therapy program reported more substantial 
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improvements in perceived coping abilities (mental health), perceived social support (social 
functioning), and mindfulness. 
  The Creative Arts Therapy is another mind-body therapeutic approach that utilizes 
the arts, such as music, art, drama, dance, and poetry in order to elicit similar relaxation 
responses as the Relaxation Response and Resiliency Program. Two publications utilized 
the creative arts therapy in order to improve the quality of life and symptoms of the patient 
population. Madden et al. (2010) showed an improvement in pain tolerance (bodily pain) in 
children with brain tumors after the Creative Arts Therapy intervention. Additionally, the 
patients were more excited, happier, and less nervous (mental health) compared to before 
intervention. Puetz et al. (2013) also showed a significant reduction in depression and 
anxiety (mental health) and pain (bodily pain), as well as an increase in quality of life in 
patients with cancer.  
 
Cognitive-Behavioral Therapies 
 The basis of cognitive-behavioral therapy is to correct the faulty assumptions or 
misconceptions an individual has toward a certain subject. It is based on the fact that people 
respond to situations based on how these situations are processed in relation to relevant 
underlying beliefs a patient might have (Hollon et al., 1994). Cognitive behavioral therapy 
aims to identify areas in an individual’s thought process that may be deemed as 
overgeneralizing, magnifying negatives, or minimizing the positives, leading to emotional 
distress and self-fulfilling prophecies. Once these errors in thinking are identified, the 
patients are then taught to think in a more all-encompassing manner in order to be able to 
look through their misconceptions and have a more positive outlook on a certain situation. 
In the case of Noroozi et al. (2017) researchers utilized a cognitive-behavioral therapy in 
order to improve the self-care methods of patients with type II Diabetes. The intervention 
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group experienced a decline in depressive symptoms (mental health) as well as an in 
increase in quality of life compared to the control group in this study. Although there was no 
specific type of cognitive-behavior therapy employed in Noroozi et al. (2017) four 
publications (n = 4), used the Acceptance and Commitment Therapy in order to improve the 
QoL of patients and minimize disease-related pain.  
 The Acceptance and Commitment Therapy is a specific domain of Cognitive 
Behavioral therapy that aims to improve the quality of life and minimize pain in adults and 
children with chronic pain (Wicksell et al., 2009). The misconception in the thought process 
of patients undergoing this sort of intervention is based on the fact that individuals with 
chronic pain tend to spend extensive energy in an attempt to avoid or control their pain 
(Martin et al., 2016). Thus, the goal of the acceptance and commitment therapy is not to rid 
the patient of pain, but instead is to change the person’s relationship with pain such that they 
do not consider it to be the defining feature of their life. This shift in perspective aims to 
allow patients to let go of the struggle against pain and instead focus on things that matter 
more to them.  
 Three publications (n = 3) utilized the Acceptance and Commitment Therapy in patients 
without NF1. Luciano et al. (2013) showed that patients with fibromyalgia demonstrated an 
improvement in coping with the disease as well as reduced pain levels (bodily pain) in a 
group therapy setting. Wicksell et al. (2012) also aimed to improve the pain and QoL in 
patients with fibromyalgia in a non-group therapy-based setting. Patients in the acceptance 
and commitment therapy group showed significant differences in pain-related functioning 
(bodily pain), mental health related QoL, and depression and anxiety (mental health) 
compared to the control group undergoing no therapy. Pankowski et al. (2017) found that 
patients with bipolar disorder reported significant improvements in anxiety and depression 
(mental health), quality of life, and psychological flexibility post-treatment. Lastly, there 
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was one NF1-specific publication by Martin et al. (2016) that utilized the acceptance and 
commitment therapy on children. In the study, patients reported significant declines in pain 
interference and intensity (bodily pain).  
Discussion 
Overview 
 The three complementary medicine approaches discussed in the previous section (The 
Relaxation Response and Resiliency Program, Creative Arts Therapy, and Acceptance and 
Commitment Therapy) not only address the domains of QoL in which NF1 patients 
experienced the most profound differences in comparison to the general population, but also 
addresses the less profound QoL domains that are still significantly lower in comparison to 
the general population. Of the six modified domains of the SF-36 questionnaire (Physical 
Functioning, Social Functioning, Vitality, Bodily Pain, General Health Perception, and 
Mental Health), the combination of all three therapy programs addresses each domain at 
least once. This is illustrated by Figure 2. The Relaxation Response and Resiliency Program 
succeeds in addressing an improvement in every domain in Figure 2. The acceptance and 
commitment therapy and creative arts therapy may not touch as many areas as the relaxation 
response and resiliency therapy, but do show potential in facilitating the improvement of 
both bodily pain and mental health. Considering that 32% of the variance in QoL in the NF1 
population comes from depression and anxiety (Cohen et al., 2015 and Ferner et al., 2017), 
mental health is a very important domain that should be focused on when implementing 
complementary medicine techniques to improve the quality of life of NF1 patients.  
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Figure 2 
Domains of the modified SF-36 questionnaire that is addressed by the therapeutic methods 
found in the literature review. 
 
 
1Indicates areas improved the Relaxation Response and Resiliency Therapy 
2Indicates areas improved by the Acceptance and Commitment Therapy 
3Indicates areas improved by the Creative Arts Therapy 
 
 In addition to finding three promising therapeutic techniques that may improve the QoL 
of NF1 patients, two additional mediums of care have been identified: videoconferencing 
and group therapy. Videoconferencing is a good alternative to weekly in-person 
appointments, especially for an individual who lives far away from their care provider. 
Vranceanu et al. (2016) actually showed a higher patient enrollment when given the 
opportunity to conduct the therapy via Skype video calls in comparison to in-person therapy 
sessions. Group therapy is another alternative treatment option, which may increase the 
efficiency of patient care. This method of treatment may only be particularly useful in large 
cities due to the rarity of the disease. Nevertheless, with multiple group therapy sessions, 
more patients can be cared for at once, allowing for a greater volume of care towards the 
NF1 population. Additionally, patients might feel more inclined to participate in the therapy 
session when they see other individuals with the same complication as them, making them 
not feel alone in the experience.  
 
 
Physical  
Functioning1 
Social  
Functioning1 
Vitality1 
Bodily Pain1,2,3   General Health Perception1 Mental Health
1,2,3 
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Addressing Limitations and Counterarguments 
 One area of this study that evokes skepticism is the measurement of QoL improvement 
in treatment plans. As stated above, the measure of QoL improvement was not explicitly 
conducted through QoL-based questionnaires. This is due to the stark lack of existing 
research that specifically addresses improvements in QoL. The primary reason for this due 
to the fact that QoL questionnaires are not necessarily the most effective ways to measure an 
improvement in a certain variable. For instance, it is much more reasonable to measure pre- 
and post-test results for depression using the Center for Epidemiologic Studies Depression 
(CESD) Scale instead of the SF-36 mental health domain. The same goes for many other 
variables measured, such as anxiety and pain. We therefore cannot explicitly state that a 
certain treatment method improved a domain of the SF-36 questionnaire. We can instead use 
inductive reasoning to hypothesize that since there was an improvement in the depression 
scores (for instance) after a certain treatment intervention, and since the mental health 
domain of the SF-36 is in part related to depression, that the mental health domain of the 
SF-36 will also show improvement after the treatment intervention.  
 Another limitation is that the variation in patient population and protocol for a specific 
treatment method such as the Relaxation Response and Resiliency Program leads to the 
combined results observed in Figure 2, meaning that no publication managed to improve so 
many domains of the SF-36 questionnaire individually. Although there is some validity to 
this argument, it can still be used to our advantage: By recognizing the subtle differences 
from publication to publication, a modified treatment plan can be devised such that 
components of each study can be included in order to produce the same aggregate results 
that were observed in Figure 2. This is an important idea to keep in mind, especially when 
evaluating the effectiveness of the NF1-specific therapies identified in the literature review. 
Since the NF1-specific studies did not necessarily have the same exact results as other 
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publications, we can use the other publications to assess aspects of the NF1-specific studies 
that might have been ineffective or less effective, such that a better-developed treatment 
plan is produced.  
 Finally, some readers might be skeptical of complementary psychosocial therapies 
altogether. One might argue the fact that many of the complications that lower the quality of 
life of patients can be treated using medicine such as antidepressants or antianxiety 
medication. Prescribing medications for every complication can be viewed partially as 
counter-intuitive. Having a large number of medications a patient must take might remind 
the patient even more of their current condition, and cause a downward spiral of negative 
emotions towards themselves and the disease. In addition, antidepressants or pain and 
anxiety medications do not actually heal the patient, they just keep the symptoms from 
presenting themselves. Once the patient stops taking his or her medications, the symptoms 
will usually reveal themselves again. In the case of complementary medicine however, there 
is no pill involved. Any change in symptom expression solely results from the mind and 
body healing themselves. Furthermore, the lack of symptoms is sustained for months post-
treatment, confirming that the patient is indeed, healthier. It might make sense, however, to 
administer traditional medical approaches in conjunction with complementary medicine in 
order to have a more profound effect, assuming that the is no issues with drug interaction.  
Future Directions in Neurofibromatosis Quality of Life Care 
In light of results of this literature review, psychosocial complementary medicine 
approaches for improving the Quality of Life of NF1 patients appears to be promising. 
Martin, Vranceanu and Zale are pioneers in implementing complementary medicine 
approaches towards the NF1 population. While their proposed therapy methods do show 
promise for the field, much more research is needed in order to develop an effective 
therapeutic plan that addresses multiple domains of QoL.  
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Based on the findings of this thesis, one future direction of this field of research is the 
implementation of a therapeutic program that incorporates the Relaxation Response and 
Resiliency Program, the Creative Arts Therapy, and the Acceptance and Commitment 
Therapy. The therapy program should provide options for participation one-on-one, via 
videoconferencing, or in a group setting, since each has its benefits and allows for patients 
to enroll in a treatment program more tailored towards their own needs.  
Another area that shows potential for future research is the INF1-QoL survey. The 
questionnaire is the first of its kind to address the QoL discrepancies of NF1 patients 
specifically. This questionnaire should be used more frequently by neuro-oncologists when 
assessing the particular domains in which NF1 patients have a diminished QoL. This 
questionnaire can also be incorporated into the potential therapeutic program proposed in 
the previous paragraph in order to have a more accurate measure on the change of QoL in 
NF1 patients post-treatment.  
Conclusion 
 The quality of life of patients with Neurofibromatosis Type 1 is significantly lower than 
that of the general population. When assessing the complications and comorbidities 
associated with the disease, it is clear why these disparities are prevalent. Due to the lack of 
promising advancements towards finding a cure for patients with this disease, it is important 
to minimize the complications of the patients. This opens the door for complementary 
medicine approaches that aim to suppress the complications experienced by patients as well 
as to improve their quality of life.  
 Through this literature review, the quality of life domains in which NF1 patients are 
most distant from the general population were identified. A second literature review was 
conducted in order to determine the most effective therapeutic methods to improve the QoL 
of the NF1 population. The Relaxation Response and Resiliency Program, Creative Arts 
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Therapy, and Acceptance and Commitment Therapy treatment plans are mind-body and 
cognitive-behavioral therapeutic methods that have been identified and shown to 
individually improve in the domains of quality of life. The work from this thesis can be used 
by institutions committed to serving the NF1 population, such as The University of Texas 
MD Anderson Cancer Center or the Department of Neurology and Cancer Center at 
Massachusetts General Hospital, or institutions committed to developing psychosocial 
therapies, such as the Benson-Henry Institute for Mind Body Medicine, to create more 
effective therapies for individuals with Neurofibromatosis Type 1. The three therapies listed 
above cover the basis for effective quality of life improvement in all domains, and 
incorporation of all three therapies into a psychosocial therapeutic program may shed light 
on more effective strategies to improve the quality of life of patients with Neurofibromatosis 
Type 1.  
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